Skip to Content

Posts tagged with "Clinical Trials"

  • Alzheimer's Disease

    Bad Investments

    Here are some sequels to stories I’ve written about here, things that have had some new chapters added to them. First off, this 2015 post mentions the steep drop in shares of Clovis Biotechnology, brought on by a rather sudden revision in the announced clinical performance of their lead drug (the covalent kinase inhibitor rociletinib). Well… Read More
  • Cancer

    IDO Inhibitors Hit a Wall

    Friday brought some very unwelcome news in oncology. I’ve written about IDO inhibitors before, partly in the context of an odd situation between Incyte and Flexus, and partly in response to a recent failed trial of a compound from NewLink. That last one shook people up a bit, but (as I mentioned in the post) Read More
  • Business and Markets

    One Of Those Binary Events for AbbVie

    Back in late 2015, I wrote about cancer stem cells, the idea that some tumors are driven by populations of slow-dividing stem cells. The theory has been that these are always going to be in there fighting against your efforts to kill off the downstream tumor cells, so unless you find a way to target… Read More
  • Clinical Trials

    Cost of Trials

    There’s been an interesting discussion about pharma R&D productivity and drug pricing on Twitter the last few days – here’s the starting point, from John Tucker. His thesis is that the hefty rate of inflation for medical services/hospitalization, where the data seem alarmingly solid, is one of the things driving the problem. T… Read More
  • Clinical Trials

    Tetraphase and Their Troubles

    I wanted to provide an update of sorts to a piece from a few years back. This was the lawsuit brought by Mark Charest against Harvard et al. over royalties relating to Tetraphase, the antibiotics company founded by Andy Myers of their chemistry department out of his group’s synthetic work in the area. Charest believed… Read More
  • Alzheimer's Disease

    More Rough Alzheimer’s News

    Man, Alzheimer’s. That’s my reaction to yesterday’s news in the field. Merck started things off with news of their last-ditch attempt to see if their beta-secretase (BACE) inhibitor verubecestat (MK-8931) could be useful. I’ve been writing about that one for a while – here’s 2012, when they announced that the com… Read More
  • Business and Markets

    Pay Your Money and Hold Your Breath

    In another example of the white-knuckle here-we-go nature of the drug business, Bristol-Myers Squibb announced this morning that they’re doing a huge deal with Nektar Therapeutics for their immune stimulant drug candidate, NKTR-214. Well, actually, they’re not getting the drug, because the development deal is non-exclusive. And theyR… Read More
  • Business and Markets

    Bristol-Myers Squibb Sows Confusion

    Yesterday was a weird day for Bristol-Myers Squibb. The company announced the results of a highly anticipated clinical trial, one combining Opdivo (nivolumab) and Yervoy (ipilimumab) in lung cancer patients. As those who follow this area know, BMS has been losing ground to Merck for the last year or two, as Merck’s Keytruda (pembrolizumab) ma… Read More
  • Clinical Trials

    A New Look at Clinical Success Rates

    Andrew Lo of MIT and his co-workers have published a really interesting paper on clinical trial probability-of-success numbers. It appears to be the largest such effort yet: In this article, we construct estimates of the POS and other related risk characteristics of clinical trials using 406 038 entries of industry- and non-industry-sponsored trial… Read More
  • Biological News

    The Landscape of Kinase Inhibitors

    I’ve been meaning to link to this article, which is the best overview I know of for kinase inhibitors. The authors (a large multicenter team led out of Munich) characterize 243 (!) kinase inhibitors that have made it into human trials across a very wide range of the known kinase enzymes, and the result is… Read More
...234...